探索PCSK9抑制剂研究的研究趋势和热点:涵盖2007年至2023年的文献计量和视觉分析
Ping Lai1,2, Shuquan Xu3, Ziyou Liu4
1Department of Cardiology, First Affiliated Hospital of Gannan Medical University, Gannan Medical University, Ganzhou, Jiangxi, China.
图书统计分析显示,蛋白转化酶9型 (PCSK9) 抑制剂研究的持续增长. 未来的研究很可能会集中在脂蛋白 (a),白酸和心血管干预.
科学领域:
- 心血管科学 心血管科学
- 药理学 药理学是指药理学的学科.
- 生物化学 生物化学
背景情况:
- 蛋白转化酶亚素/素9型 (PCSK9) 抑制剂代表了心血管治疗的重大进步.
- 尽管研究迅速增长,但对PCSK9抑制剂领域缺乏全面的文献分析.
研究的目的:
- 进行PCSK9抑制剂研究的文献分析.
- 确定当前的研究热点,并预测该领域的未来趋势.
主要方法:
- 在Web of Science核心集合 (WoSCC) 中进行系统的文献搜索.
- 包括1,812篇关于PCSK9抑制剂的学术文章和评论.
- 使用Excel,VOSviewer和CiteSpace进行数据分析和可视化.
主要成果:
- 美国在出版量 (776篇论文) 和引用量方面处于领先地位.
- 主要的机构和期刊包括Amgen和临床脂质学杂志.
- 新兴的关键词表明对脂蛋白 (a),白酸和外围动脉疾病的兴趣日益增长.
结论:
- 对PCSK9抑制剂的研究显示出一致的上升趋势.
- 美国在PCSK9抑制剂研究中占据主导地位.
- 未来的研究很可能将集中在脂蛋白 (a),贝佩多酸,皮肤冠状动脉干预,外周动脉疾病和内皮功能障碍上.
更多相关视频
08:31Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions
Published on: December 1, 2020
07:49Global and Current Research Trends of Single-Cell Sequencing in Cancer: A Bibliometric and Visualization Study
Published on: April 18, 2025
相关概念视频
Analysis of Population Pharmacokinetic Data
Model-Independent Approaches for Pharmacokinetic Data: Noncompartmental Analysis
One important characteristic of noncompartmental analyses is that drug exposure increases proportionally with increasing doses. This...
Structure-Activity Relationships and Drug Design
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
Targeted Cancer Therapies
There are several types of targeted therapies against...
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
